<p>威廉·布莱尔分析师安德鲁·布拉克曼（Andrew Brackmann）对 BFLY 股票维持看涨态度，并于 12 月 8 日给予买入评级。</p>
<p>安德鲁·布拉克曼给予买入评级的原因是多种因素的结合，这些因素突显了蝴蝶网络（Butterfly Network）在短期内的稳定性和长期的上行潜力。他指出，管理层正进入他们认为的关键时期，2026 年被视为投资者可能开始认识到公司技术价值的一年，超越传统的床边超声。早期的 traction 迹象，如与 Midjourney 的合作以及合作伙伴对蝴蝶的超声芯片平台在非床边超声应用中部署的强烈兴趣，表明潜在的收入机会可能远大于核心业务本身。</p>
<p>与此同时，布拉克曼认为当前的运营趋势支持投资案例，POCUS 领域的需求正在改善，并对满足第四季度和 2026 年收入预期充满信心。尽管 2025 年面临与美国国际开发署（USAID）相关的资金削减和医院报销不确定性带来的暂时阻力，但管理层认为这些压力是短暂的，预计推迟的企业交易将在 2026 年实现。在他看来，核心业务的韧性、可扩展市场的扩大以及快速发展的差异化技术平台的结合，显著降低了风险，并为股价的实质性上涨创造了空间，这也是他重申买入建议的依据。</p>

BFLY

半导体 3 倍做多 - Direxion

<p>威廉·布莱尔分析师安德鲁·布拉克曼重申对 Butterfly Network (BFLY) 股票的买入评级，指出近期的稳定性和长期的增长潜力。关键因素包括通往 2026 年的关键时期、超越传统超声波的扩展机会，以及对超声波芯片平台的强烈兴趣。尽管 2025 年面临挑战，管理层预计到 2026 年将实现复苏，支持股价的显著上涨</p>

<p>William Blair analyst Andrew Brackmann has maintained their bullish stance on BFLY stock, giving a Buy rating on December 8.</p>
<div class="lb-trans"><p>威廉·布莱尔分析师安德鲁·布拉克曼（Andrew Brackmann）对 BFLY 股票维持看涨态度，并于 12 月 8 日给予买入评级。</p>
</div><p>Andrew Brackmann has given his Buy rating due to a combination of factors that highlight both Butterfly Network’s near-term stability and long-term upside. He notes that management is entering what they view as a pivotal period, with 2026 positioned as a year when investors may start to recognize the value of the company’s technology beyond traditional point-of-care ultrasound. Early signs of traction, such as the Midjourney collaboration and strong interest from partners seeking to deploy Butterfly’s Ultrasound-on-Chip platform in non-POCUS applications, suggest a potentially much larger revenue opportunity than the core business alone.</p>
<div class="lb-trans"><p>安德鲁·布拉克曼给予买入评级的原因是多种因素的结合，这些因素突显了蝴蝶网络（Butterfly Network）在短期内的稳定性和长期的上行潜力。他指出，管理层正进入他们认为的关键时期，2026 年被视为投资者可能开始认识到公司技术价值的一年，超越传统的床边超声。早期的 traction 迹象，如与 Midjourney 的合作以及合作伙伴对蝴蝶的超声芯片平台在非床边超声应用中部署的强烈兴趣，表明潜在的收入机会可能远大于核心业务本身。</p>
</div><p>At the same time, Brackmann sees the current operating trends as supportive of the investment case, with improving demand in the POCUS segment and confidence in meeting both fourth-quarter and 2026 revenue expectations. While 2025 faced temporary headwinds from funding cuts tied to USAID and uncertainties around hospital reimbursement, management views these pressures as short-lived, with delayed enterprise deals expected to materialize in 2026. In his view, the combination of a resilient core business, an expanding addressable market, and a rapidly evolving, differentiated technology platform meaningfully de-risks the story and creates room for substantial share price appreciation, underpinning his decision to reaffirm a Buy recommendation.</p>
<div class="lb-trans"><p>与此同时，布拉克曼认为当前的运营趋势支持投资案例，POCUS 领域的需求正在改善，并对满足第四季度和 2026 年收入预期充满信心。尽管 2025 年面临与美国国际开发署（USAID）相关的资金削减和医院报销不确定性带来的暂时阻力，但管理层认为这些压力是短暂的，预计推迟的企业交易将在 2026 年实现。在他看来，核心业务的韧性、可扩展市场的扩大以及快速发展的差异化技术平台的结合，显著降低了风险，并为股价的实质性上涨创造了空间，这也是他重申买入建议的依据。</p>
</div>

Butterfly Network：坚韧的核心业务和扩展的芯片超声波机会推动了重申的买入评级